Anti-Herpetic Treatment of Genital Ulcer : Effect on HIV & Herpes Shedding (ANRS 1212)
Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
Herpes virus type 2 (HSV-2) infection - as a cofactor of human immunodeficiency virus (HIV)
transmission - can be targeted by anti-herpetic specific drugs, either as a continuous
prophylactic treatment during its asymptomatic shedding phase, or as an episodic treatment
during clinically-apparent genital ulcerations. The main objective of this trial will be to
demonstrate that acyclovir treatment given during clinical episodes (primary infection or
recurrences) can reduce genital shedding of HIV, thereby contributing to a reduction of HIV
infectiousness of dually infected individuals (HIV+/HSV+).
Phase:
Phase 2
Details
Lead Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis